Compare AGRO & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGRO | ANIP |
|---|---|---|
| Founded | 2002 | 2001 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2011 | 1999 |
| Metric | AGRO | ANIP |
|---|---|---|
| Price | $14.04 | $72.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $9.33 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 2.1M | 326.6K |
| Earning Date | 03-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 3.32 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | $16.27 | $23.05 |
| Revenue Next Year | $0.06 | $14.08 |
| P/E Ratio | $37.52 | ★ $22.30 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $6.89 | $56.71 |
| 52 Week High | $14.95 | $99.50 |
| Indicator | AGRO | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 70.45 | 41.52 |
| Support Level | $7.67 | $71.29 |
| Resistance Level | N/A | $84.47 |
| Average True Range (ATR) | 0.93 | 2.30 |
| MACD | 0.22 | 0.15 |
| Stochastic Oscillator | 87.30 | 34.97 |
Adecoagro SA is a Luxembourg-based agricultural company. It is involved in a wide range of businesses, including farming crops and other agricultural products, dairy operations sugar, ethanol, energy production, and land transformation. The group operates in two lines of business, namely, Farming and Sugar, Ethanol and Energy. The Farming is further comprised of three reportable segments: Crops, Rice and Dairy. Sugar, Ethanol and Energy Segment, consists of cultivating sugarcane, which is processed in owned sugar mills, transformed into ethanol, sugar and electricity, in addition to biomethane and then marketed.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.